Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

Journal of Immunological Methods

Volumn 434, Issue , 2016, Pages 1-8

  Chen, Fang ^a   Teachey, David T ^b   Pequignot, Edward ^a   Frey, Noelle ^a   Porter, David ^a   Maude, Shannon L ^b   Grupp, Stephan A ^b   June, Carl H ^a   Melenhorst, Jan J ^a   Lacey, Simon F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Children's Hospital of Pennsylvania   (United States)

Author keywords

CAR T; IL 6; Luminex; SIL6 R; Siltuximab; Tocilizumab

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SILTUXIMAB; TOCILIZUMAB; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD LEVEL; CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOASSAY; IMMUNOLOGY TEST KIT; IMMUNOTHERAPY; MEASUREMENT ACCURACY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; PENNSYLVANIA; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-6; LEUKEMIA; LYMPHOMA; MOLECULAR TARGETED THERAPY; PENNSYLVANIA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84963704157     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2016.03.005     Document Type: Article

References (28)

1. Butler J.E., Spradling J.E., Suter M., Dierks S.E., Heyermann H., Peterman J.H. The immunochemistry of sandwich ELISAs-I. The binding characteristics of immunoglobulins to monoclonal and polyclonal capture antibodies adsorbed on plastic and their detection by symmetrical and asymmetrical antibody-enzyme conjugates. Mol. Immunol. 1986, 23(9):971-982.
2. Calabrese L.H., Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 2014, 10(12):720-727.
3. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 2010, 56(2):186-193.
4. FDA. ACTEMRA® (tocilizumab) . http://wwwaccessdatafdagov/drugsatfda_docs/label/2010/125276lblpdf.
5. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368(16):1509-1518.
6. JanssenBiotech. SYLVANT (siltuximab) . http://wwwjanssenbiotechcom/sites/default/files/pdf/SYLVANTPrescribingInformationpdf.
7. June C.H., Maus M.V., Plesa G., et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother 2014, 63(9):969-975.
8. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015, 33(6):540-549.
9. Lee D.W., Gardner R., Porter D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014, 124(2):188-195.
10. Leng S.X., McElhaney J.E., Walston J.D., Xie D., Fedarko N.S., Kuchel G.A. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63(8):879-884.
11. LH Calabrese, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014, 10(12):720-727.
12. Maude S.L., Barrett D., Teachey D.T., Grupp S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014, 20(2):119-122.
13. Maude S.L., Frey N., Shaw P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371(16):1507-1517.
14. Maude S.L., Teachey D.T., Porter D.L., Grupp S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015, 125(26):4017-4023.
15. Mihara M., Kasutani K., Okazaki M., et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 2005, 5(12):1731-1740.
16. Nishina N., Kikuchi J., Hashizume M., Yoshimoto K., Kameda H., Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis 2013, 73(5):945-947.
17. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K., Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005, 29(4):169-175.
18. Porter D.L., Hwang W.T., Frey N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015, 2(303):303ra139.
19. Robak T., Gladalska A., Stepien H., Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediat. Inflamm. 1998, 7(5):347-353.
20. Rossi J.F., Lu Z.Y., Jourdan M., Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015, 21(6):1248-1257.
21. Scheller J., Rose-John S. The interleukin 6 pathway and atherosclerosis. Lancet 2012, 380(9839):338.
22. Simpson R.J., Hammacher A., Smith D.K., Matthews J.M., Ward L.D. Interleukin-6: structure-function relationships. Protein Sci. 1997, 6(5):929-955.
23. Thompson D.K., Huffman K.M., Kraus W.E., Kraus V.B. Critical appraisal of four IL-6 immunoassays. PLoS One 2012, 7(2).
24. Vignali D.A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 2000, 243(1-2):243-255.
25. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94(7):2217-2224.
26. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014, 70(1):11-20.
27. Xu X.J., Tang Y.M. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014, 343(2):172-178.
28. Zaki M.H., Nemeth J.A., Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer 2004, 111(4):592-595.